Dr Kate Moodie
Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology
30 Scholarly works
1 Projects
HIGHLIGHTS
2025
Journal article
Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors
DOI: 10.1016/j.breast.2025.1045862025
Journal article
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
DOI: 10.1038/s41591-025-03704-92025
Journal article
A radiation therapy platform to enable upright cone beam computed tomography and future upright treatment on existing photon therapy machines
DOI: 10.1002/mp.175232024
Journal article
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
DOI: 10.1016/S1470-2045(23)00529-62023
Conference Proceedings
Local anaesthetic improves patient experience of breast and melanoma lymphoscintigraphy
2022
Research grants (other domestic)
Sitting Up for Radiotherapy
2019
Journal article
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2– positive metastatic breast cancer
DOI: 10.1158/2159-8290.CD-18-1151
RECENT SCHOLARLY WORKS
2023
Journal article
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme
DOI: 10.1111/his.149062023
Conference Proceedings
Association between baseline radiological tumor burden and outcomes in patients with metastatic breast cancer treated with an immune checkpoint inhibitor
DOI: 10.1200/jco.2023.41.16_suppl.11032023
Conference Proceedings
Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.
2023
Other
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
DOI: 10.1158/2159-8290.225410742023
Other
Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
DOI: 10.1158/2159-8290.c.6549547